enGene Holdings Inc.
NASDAQ:ENGNBiotechnology
-$0.02 today
- Market cap
- $115.27M
- Beta
- -0.29
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.95
Volume 1.64M
Average 1.58M
ENGN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
enGene Holdings Inc.NASDAQ: ENGN
EBITDA · Q2 FY2026 · quarter ended Apr 2026
EBITDA remains negative
Q2 FY2026 EBITDA was -$31.79M, compared with -$24.74M a year earlier. Trailing-twelve-month EBITDA was -$125.94M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 8 analysts of $0 (+100.0%) for the fiscal year ending Oct 2026, a step up from the -118.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterApr 2026
- -$31.79M-10.3% QoQ
- Last fiscal yearOct 2025
- -$113.8M-118.7% YoY
- LTMApr 2026
- -$125.94M-65.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -28.5% | +100.0% | +128.5 pp |
| 1 year | -118.7% | +100.0% | +218.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (113.8M) USD
- Year-over-year change
- -118.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | (113.8M) | -118.7% |
| FY2024 | 2024-10-31 | (52.04M) | +45.1% |
| FY2023 | 2023-10-31 | (94.77M) | -316.0% |
| FY2022 | 2022-10-31 | (22.78M) | -25.5% |
| FY2021 | 2021-10-31 | (18.15M) | — |
EBITDA vs competitors
How ENGN compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -65.1% is the 9th highest of 10, against a peer median of -17.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$5.14M USD | +92.4% | — | 2.4% | |
| LTM Mar 2026 | -$51.11M USD | -57.3% | — | 75.1% | |
| LTM Mar 2026 | -CHF 64.45M CHF | -29.6% | — | 1740.8% | |
| LTM Mar 2026 | -$71.29M USD | -16.9% | — | — | |
| LTM Mar 2026 | -$78.13M USD | — | — | 8478.5% | |
| LTM Mar 2026 | -$78.15M USD | +14.5% | — | 2034.0% | |
| LTM Mar 2026 | -$88.27M USD | +2.7% | — | 245200.0% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | -$125.94M USD | -65.1% | — | — |
| LTM Mar 2026 | -$159.48M USD | -49.1% | — | — | |
| LTM Mar 2026 | -$165.68M USD | -74.6% | — | — | |
| LTM Mar 2026 | -$193.41M USD | -17.1% | — | — | |
| Peer median (excluding ENGN) | — | -17.1% | — | 1887.4% | |
Competitors are the stored peer set for ENGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 12.46M | 15.47M | 16.46M | 38.32M | 94.48M |
| Selling, General & Admin | 3.16M | 3.26M | 8.47M | 23.98M | 28.69M |
| Operating Expenses | 15.87M | 19.43M | 26.06M | 62.3M | 123.17M |
| Depreciation & Amortization | 272K | 238K | 175K | 323K | 509K |
| EBITDA | (18.15M) | (22.78M) | (94.77M) | (52.04M) | (113.8M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (15.87M) | (19.43M) | (26.06M) | (62.3M) | (123.17M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 25K | 129K | 1.12M | 10.41M | 9.43M |
| Interest Expense | 5.02M | 1.42M | 4.95M | 2.8M | 2.99M |
| Other Income / Expenses | (7.57M) | (5.01M) | (73.84M) | 7.14M | 5.86M |
| Income Before Tax | (23.44M) | (24.44M) | (99.9M) | (55.16M) | (117.3M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 22K | 17K | (19K) | 0 |
| Net Income | (23.44M) | (24.46M) | (99.92M) | (55.14M) | (117.3M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.01) | 0.00 | (4.24) | (1.46) | (2.29) |
| EPS (Diluted) | (0.01) | 0.00 | (4.24) | (1.46) | (2.29) |
| Weighted Avg Shares | 15.81M | 15.81M | 23.56M | 44.64M | 51.12M |
| Weighted Avg Shares (Diluted) | 15.81M | 15.81M | 23.56M | 44.64M | 51.12M |
enGene Holdings Inc.
NASDAQ:ENGN
Intrinsic Alpha fair value
Locked
Current Price
$1.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.